RPHM
Reneo Pharmaceuticals Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. many of these diseases are associated with deficits in cellular metabolism and energy production. our goal is to improve daily function and quality of life of patients suffering from these diseases, most specifically, by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness and wasting. we are currently advancing a novel molecule into several diseases. our experienced team of drug development experts, who have collaborated in many successful programs, are dedicated and passionate about finding effective therapies for these complex rare diseases.
Market Cap: 54 Million
Primary Exchange: NASDAQ
Website: reneopharma.com
Shares Outstanding: 33.3 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.3920677351058552
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Ethical Flags
Longest drawdown: 236 trading days
From: 2023-04-21 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|